Related references
Note: Only part of the references are listed.The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015
Andrew G. Nicholson et al.
JOURNAL OF THORACIC ONCOLOGY (2022)
Pulmonary Lymphoepithelioma-Like Carcinoma Treated with Immunotherapy or Chemotherapy: A Single Institute Experience
Yang Fu et al.
ONCOTARGETS AND THERAPY (2021)
A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy
Miguel F. Sanmamed et al.
CANCER DISCOVERY (2021)
LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types
Landon C. Brown et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Gene expression and immune infiltration in melanoma patients with different mutation burden
Liwei Wang et al.
BMC CANCER (2021)
Immune Checkpoint Blockade Therapy May Be a Feasible Option for Primary Pulmonary Lymphoepithelioma-like Carcinoma
Zuohong Wu et al.
FRONTIERS IN ONCOLOGY (2021)
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial
Hai-Qiang Mai et al.
NATURE MEDICINE (2021)
Molecular characteristics of primary pulmonary lymphoepithelioma-like carcinoma based on integrated genomic analyses
Bojiang Chen et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
A multicenter analysis of genomic profiles and PD-L1 expression of primary lymphoepithelioma-like carcinoma of the lung
Zhanhong Xie et al.
MODERN PATHOLOGY (2020)
Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma-like carcinoma
Kai Yin et al.
THORACIC CANCER (2020)
Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected first-line metastatic non-small cell lung carcinoma
M. Majem et al.
ANNALS OF ONCOLOGY (2020)
Treatment of pembrolizumab and chemotherapy results in pulmonary lymphoepithelioma-like carcinoma progression through harboring secondary amplification of PI3KCA and IL-7R
Mei-ting Chen et al.
LUNG CANCER (2020)
Overcoming resistance to anti-PD-1 immunotherapy in lymphoepithelioma-like carcinoma: A case report and review of the literature
Zhengwu Tang et al.
LUNG CANCER (2020)
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial
Yi-Long Wu et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis
Ila Datar et al.
CLINICAL CANCER RESEARCH (2019)
Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell Lung Cancer
Wenfeng Fang et al.
CLINICAL CANCER RESEARCH (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma
Shaodong Hong et al.
NATURE COMMUNICATIONS (2019)
Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma
Chao Zhang et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
A Randomized Phase 3 Study of Camrelizumab plus Chemotherapy as 1st Line Therapy for Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
C. Zhou et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Primary Pulmonary Lymphoepithelioma-Like Carcinoma Response Favorably To Nivolumab: A Case Report
Zhi-Xin Qiu et al.
ONCOTARGETS AND THERAPY (2019)
EBV-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma Response to PD-L1 Blockade
Anand Narayanan et al.
CLINICAL LUNG CANCER (2019)
Immunotherapy for LELC: Case Report and a Focused Review
Marie Darrason et al.
CLINICAL LUNG CANCER (2019)
TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade In Vitro and In Vivo
Srimoyee Ghosh et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
Thorough survey and analysis of pulmonary lymphoepithelioma-like carcinoma in Macau and multimodality treatment for advanced disease
Na Zhou et al.
LUNG CANCER (2019)
Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria
M. Tazdait et al.
EUROPEAN JOURNAL OF CANCER (2018)
Clinical Significance of Plasma Epstein-Barr Virus DNA in Pulmonary Lymphoepithelioma-like Carcinoma (LELC) Patients
Mian Xie et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base
Xiao-Dong Jiao et al.
LUNG CANCER (2018)
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
Seung Tae Kim et al.
NATURE MEDICINE (2018)
PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux
Jake S. O'Donnell et al.
SEMINARS IN CANCER BIOLOGY (2018)
Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates
Yannick Simoni et al.
NATURE (2018)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer
Qingzhu Jia et al.
NATURE COMMUNICATIONS (2018)
TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy
Heng-Jia Liu et al.
JCI INSIGHT (2018)
Response of advanced stage recurrent lymphoepithelioma-like carcinoma to nivolumab
Vivek Kumar et al.
IMMUNOTHERAPY (2017)
Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study
Chiun Hsu et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance
Zhen Wang et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Advanced primary pulmonary lymphoepithelioma-like carcinoma: clinical manifestations, treatment, and outcome
Chun-Yu Lin et al.
JOURNAL OF THORACIC DISEASE (2017)
Lung Cancer-Major Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual
Ramon Rami-Porta et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Are virus-induced cancers more sensitive to checkpoint inhibitors?
Hassan Kanaan et al.
FUTURE ONCOLOGY (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
Kei Muro et al.
LANCET ONCOLOGY (2016)
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Geoffrey T. Gibney et al.
LANCET ONCOLOGY (2016)
Clinicopathological features and prognosis of primary pulmonary lymphoepithelioma-like carcinoma
Wen-Yang Jiang et al.
JOURNAL OF THORACIC DISEASE (2016)
Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature
Chul Kim et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2016)
Classifying Cancers Based on T-cell Infiltration and PD-L1
Michele W. L. Teng et al.
CANCER RESEARCH (2015)
PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy
Yih-Leong Chang et al.
LUNG CANCER (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Positive expression of programmed death ligand-1 correlates with superior outcomes and might be a therapeutic target in primary pulmonary lymphoepithelioma-like carcinoma
Li Jiang et al.
ONCOTARGETS AND THERAPY (2015)
PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival
Wenfeng Fang et al.
ONCOTARGET (2015)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
The Epstein-Barr Virus G-Protein-Coupled Receptor Contributes to Immune Evasion by Targeting MHC Class I Molecules for Degradation
Jianmin Zuo et al.
PLOS PATHOGENS (2009)
Lymphoepithelioma-like carcinoma of the lung
James C. Ho et al.
RESPIROLOGY (2006)
Share Paper
